Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$123.35
-0.7%
$115.23
$96.43
$153.84
$35.04B1.231.84 million shs1.38 million shs
Danaher Corporation stock logo
DHR
Danaher
$204.80
-0.3%
$196.05
$171.00
$281.70
$146.57B0.773.49 million shs2.37 million shs
Repligen Corporation stock logo
RGEN
Repligen
$130.19
-2.8%
$125.65
$102.97
$182.52
$7.31B1.11724,395 shs757,950 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$54.14
-0.5%
$50.22
$46.01
$83.62
$8.49B1.391.47 million shs1.42 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
0.00%+1.81%+5.46%+17.26%-6.71%
Danaher Corporation stock logo
DHR
Danaher
0.00%+0.85%+2.14%+6.10%-16.98%
Repligen Corporation stock logo
RGEN
Repligen
0.00%+2.22%+2.09%+2.30%+3.39%
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.00%+1.89%+7.17%+3.06%-29.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
4.701 of 5 stars
3.35.02.53.62.20.81.3
Danaher Corporation stock logo
DHR
Danaher
4.8907 of 5 stars
3.43.01.74.34.23.31.3
Repligen Corporation stock logo
RGEN
Repligen
4.6008 of 5 stars
4.31.00.04.51.61.71.9
Bio-Techne Corp stock logo
TECH
Bio-Techne
4.8892 of 5 stars
4.33.01.74.22.11.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
2.54
Moderate Buy$139.7713.31% Upside
Danaher Corporation stock logo
DHR
Danaher
2.85
Moderate Buy$248.4321.31% Upside
Repligen Corporation stock logo
RGEN
Repligen
2.69
Moderate Buy$170.7531.15% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.50
Moderate Buy$70.0029.29% Upside

Current Analyst Ratings Breakdown

Latest RGEN, TECH, A, and DHR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Danaher Corporation stock logo
DHR
Danaher
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Sector Outperform$275.00
7/11/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$90.00 ➝ $75.00
7/9/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00
7/8/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$125.00 ➝ $130.00
7/8/2025
Danaher Corporation stock logo
DHR
Danaher
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$230.00 ➝ $226.00
7/8/2025
Repligen Corporation stock logo
RGEN
Repligen
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$140.00 ➝ $130.00
6/24/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $125.00
6/24/2025
Danaher Corporation stock logo
DHR
Danaher
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00 ➝ $225.00
6/24/2025
Repligen Corporation stock logo
RGEN
Repligen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$150.00
6/5/2025
Danaher Corporation stock logo
DHR
Danaher
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$240.00 ➝ $235.00
6/5/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$6.51B5.38$6.26 per share19.72$20.53 per share6.01
Danaher Corporation stock logo
DHR
Danaher
$23.88B6.14$10.92 per share18.75$68.60 per share2.99
Repligen Corporation stock logo
RGEN
Repligen
$650.43M11.25$3.11 per share41.90$35.21 per share3.70
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.16B7.32$2.31 per share23.40$13.13 per share4.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$1.29B$4.0530.4620.293.7417.59%25.92%13.24%8/20/2025 (Estimated)
Danaher Corporation stock logo
DHR
Danaher
$3.90B$5.1539.7723.902.8815.81%10.80%6.89%7/22/2025 (Estimated)
Repligen Corporation stock logo
RGEN
Repligen
-$25.51M-$0.45N/A55.173.73-3.93%4.53%3.17%7/29/2025 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$168.10M$0.8266.0327.482.5710.89%13.17%10.17%8/6/2025 (Estimated)

Latest RGEN, TECH, A, and DHR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q4 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.49N/AN/AN/A$315.14 millionN/A
7/29/2025Q2 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.40N/AN/AN/A$174.62 millionN/A
7/22/2025Q2 2025
Danaher Corporation stock logo
DHR
Danaher
$1.64N/AN/AN/A$5.83 billionN/A
5/28/2025Q2 2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$1.26$1.31+$0.05$0.75$1.63 billion$1.67 billion
5/7/2025Q3 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
4/29/2025Q1 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.35$0.39+$0.04$0.10$163.65 million$169.17 million
4/22/2025Q1 2025
Danaher Corporation stock logo
DHR
Danaher
$1.62$1.88+$0.26$1.32$5.58 billion$5.74 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$0.990.80%N/A24.44%9 Years
Danaher Corporation stock logo
DHR
Danaher
$1.280.63%N/A24.85%2 Years
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.59%N/A39.02%N/A

Latest RGEN, TECH, A, and DHR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Danaher Corporation stock logo
DHR
Danaher
quarterly$0.320.67%6/27/20257/25/2025
5/22/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
quarterly$0.24800.9%7/1/20257/1/20257/23/2025
5/19/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
0.55
2.09
1.60
Danaher Corporation stock logo
DHR
Danaher
0.31
1.43
1.05
Repligen Corporation stock logo
RGEN
Repligen
0.27
6.79
5.79
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.16
3.71
2.58

Institutional Ownership

CompanyInstitutional Ownership
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
N/A
Danaher Corporation stock logo
DHR
Danaher
79.05%
Repligen Corporation stock logo
RGEN
Repligen
97.64%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
N/A
Danaher Corporation stock logo
DHR
Danaher
11.20%
Repligen Corporation stock logo
RGEN
Repligen
1.20%
Bio-Techne Corp stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
17,900284.07 millionN/AOptionable
Danaher Corporation stock logo
DHR
Danaher
63,000715.67 million635.52 millionOptionable
Repligen Corporation stock logo
RGEN
Repligen
1,77856.18 million55.51 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.77 million150.65 millionOptionable

Recent News About These Companies

Scotiabank Cuts Bio-Techne (NASDAQ:TECH) Price Target to $75.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Agilent Technologies stock logo

Agilent Technologies NYSE:A

$123.35 -0.82 (-0.66%)
Closing price 07/11/2025 03:58 PM Eastern
Extended Trading
$124.99 +1.64 (+1.33%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Danaher stock logo

Danaher NYSE:DHR

$204.80 -0.71 (-0.35%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$200.85 -3.95 (-1.93%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Repligen stock logo

Repligen NASDAQ:RGEN

$130.19 -3.81 (-2.84%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$127.77 -2.42 (-1.86%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$54.14 -0.27 (-0.50%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$53.56 -0.59 (-1.08%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.